

PATENT ATTORNEY DOCKET NUMBER: 00786/351005

| Certificate of Mailing: Date of Deposit: August 1, 2001 | |
|---|---------|
| I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231. | CH CENT |
| Colleen Coyne Printed name of person mailing correspondence Signature of person mailing correspondence | 77 100 |
| | - K |

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Gary Ruvkun et al.

Art Unit:

1633

Serial No.:

09/844,353

Examiner:

Filed:

April 27, 2001

Customer No.:

21559

Title:

THERAPEUTIC AND DIAGNOSTIC TOOLS FOR IMPAIRED

GLUCOSE TOLERANCE CONDITIONS

Assistant Commissioner For Patents Washington, D.C. 20231

REPLY TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING **NUCLEOTIDE AND/OR AMINO ACID SEQUENCES**

In reply to the Notice To Comply mailed June 4, 2001, Applicant submits the following:

- A substitute paper copy of the sequence listing and an amendment directing its entry into the specification.
 - A substitute copy of the sequence listing in computer readable form.
- A statement that the contents of the paper and computer readable copies are the same and contain no new matter.

If there are any charges, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 1 August 2001

Karen L. Elbing, Ph.D. Reg. No. 35,238

Clark & Elbing LLP 176 Federal Street Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

\Clark-w2k1\documents\00786\351xxx\00786.351005 Reply to Notice to Comply.wpd



PATENT

ATTORNEY DOCKET NUMBER: 00786/351005

Certificate of Mailing: Date of Deposit: August 1, 2001

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner of Patents, Washington, D.C. 20231.

Colleen Coyne

Printed name of person mailing correspondence

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Gary Ruvkun et al.

Art Unit:

1633

Serial No.:

09/844,353

Examiner:

Filed:

April 27, 2001

Customer No.:

21559

Title:

THERAPEUTIC AND DIAGNOSTIC TOOLS FOR IMPAIRED

GLUCOSE TOLERANCE CONDITIONS

Assistant Commissioner For Patents Washington, D.C. 20231

STATEMENT UNDER 37 C.F.R. § 1.825

In reply to the Notice to Comply mailed June 4, 2001 and as required by 37 C.F.R. § 1.825(a), enclosed is an amended sequence listing consisting of 63 sheets to be inserted at the end of the application.

The amendments correct typographical errors. I hereby submit that the substitute sheets contain no new matter.

As required by 37 C.F.R. § 1.825(b), enclosed is a diskette containing a copy of the sequence listing in computer readable form including all previously submitted data with the amendments incorporated therein. The contents of the computer readable form are the same as the contents of the paper sheets.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: 1 August 2001

Clark & Elbing LLP 176 Federal Street Boston, MA 02110 Telephone: 617-428-0200

Facsimile: 617-428-7045

\Clark-w2k1\documents\00786\351xxx\00786.351005 Sequence Statement for Reply.wpd



AUG 0 8 2001

United States Patent and Trademark Office

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20 231

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/844,353

04/27/2001

Gary Ruvkun

00786/351005

CONFIRMATION NO. 3561

21559 CLARK & ELBING LLP 176 FEDERAL STREET BOSTON, MA 02110-2214 FORMALITIES LETTER
OC000000006144404

Date Mailed: 06/04/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content
of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823,
as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a
substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the
content of the sequence listing information recorded in computer readable form is identical to the
written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as
required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE